Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Manuel Pombo-Suarez¹, Carlos Sanchez-Piedra², Juan J Gomez-Reino³, Kim Lauper⁴, Nevsun Inanc⁵, Anja Strangfeld⁶, Doreen Huschek⁷, Karel Pavelka⁸, Eirik Kristianslund⁹, Tore Kvien¹⁰, Ziga Rotar¹¹, Dan Nordström¹², Denis Choquette¹³, Ori Elkayam¹⁴, Burkhard Leeb¹⁵, Maria José Santos¹⁶, Kimme Hyrich¹⁷, Lianne Kearsley-Fleet¹⁸, Catalin Codreanu¹⁹, Denis Monguin²⁰, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁴Geneva University Hospitals, Geneve, Switzerland, ⁵Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹²Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ¹³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ¹⁴Tel Aviv Medical Center, Tel Aviv, Israel, ¹⁵Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, ¹⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁹Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²⁰Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²¹University Hospital of Geneva, Geneve - Vesenaz, Switzerland
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…
Abstract Number: 0263 • ACR Convergence 2021
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴, Laura Schanberg⁵ and Yukiko Kimura⁶, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Seattle Children's Hospital, Seattle, WA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Duke University Medical Center, Durham, NC, ⁶Hackensack University Medical Center, New York, NY
Background/Purpose: Although the increasing availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved outcomes for patients with Juvenile Idiopathic…
Abstract Number: 0816 • ACR Convergence 2021
Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
Rieke Alten¹, Xavier Mariette², Rene-Marc Flipo³, Roberto Caporali⁴, Maya Buch⁵, Yusuf Patel⁶, Raimon Sanmarti⁷, Sara Marsal⁸, Michael Nurmohamed⁹, Hedley Griffiths¹⁰, Peter Peichl¹¹, Bettina Bannert¹², Adrian Forster¹³, Melanie Chartier¹⁴, Yedid Elbez¹⁵, Christiane Rauch¹⁶, Vadim Khaychuk¹⁷ and Karissa Lozenski¹⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Centre Hospitalier Universitaire de France, Lille, France, ⁴Policlinico S. Matteo University, Pavia, Italy, ⁵University of Leeds, Leeds, United Kingdom, ⁶Hull Royal Infirmary, Hull, United Kingdom, ⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹⁰Barwon Rheumatology Service, Geelong, Australia, ¹¹Evangelical Hospital, Vienna, Austria, ¹²Universitätsspital Basel, Basel, Switzerland, ¹³Schulthess Klinik, Zürich, Switzerland, ¹⁴Bristol Myers Squibb, Rueil-Malmaison, France, ¹⁵Deepscover, Puteaux, France, ¹⁶Bristol Myers Squibb, Munich, Germany, ¹⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic…
Abstract Number: 1038 • ACR Convergence 2021
Outcomes of Hydroxychloroquine Screening for Retinopathy in a Cohort of Patients with Rheumatological Conditions
Ghazala Tehseen¹, Alexandra Chadwick², Sarah Wills² and Audrey Low², ¹Faculty of Biology, Medicine and Health. The University of Manchester, Manchester, UK, Manchester, United Kingdom, ²Rheumatology Department, Salford Royal NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Hydroxychloroquine (HCQ) is used to treat rheumatoid arthritis (RA), connective tissue disease (CTD) and other inflammatory conditions. In 2018, the United Kingdom Royal College…
Abstract Number: 1444 • ACR Convergence 2021
Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Ahmad Sherbini¹, James Gwinnutt¹, Kimme Hyrich¹ and Suzanne Verstappen², ¹University of Manchester, Manchester, United Kingdom, ²School of Social Sciences, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is the first-line treatment in the management of patients with rheumatoid arthritis (RA) due to its good efficacy. However, certain adverse events,…
Abstract Number: 1695 • ACR Convergence 2021
Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment
Renske Hebing¹, Sohaila Mahmoud¹, Marry Lin², Ittai Muller², Sandra Heil³, Willem Lems⁴, Mike Nurmohamed⁵, Robert de Jonge² and Gerrit Jansen², ¹Reade, Amsterdam, Netherlands, ²AmsterdamUMC, Amsterdam, Netherlands, ³ErasmusMC, Rotterdam, Netherlands, ⁴VUmc, Amsterdam, Netherlands, ⁵Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Optimal dosing of methotrexate (MTX) for individual rheumatoid arthritis (RA) patients to achieve adequate disease control remains challenging. Assessment of erythrocyte MTX-polyglutamates (PGs) levels…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0819 • ACR Convergence 2021
A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Mohamed Tageldin¹, Malavikalakshmi Attur², Nicole Wilson¹, Rebecca Schorr³ and Tarun Sharma¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Drexel University School of Medicine, Philadelphia, PA, ³Highmark Health, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Patients with chronic RA remain…
Abstract Number: 1087 • ACR Convergence 2021
The Humoral Immunity of mRNA-Based SARS-CoV2 Vaccine in Autoimmune Rheumatic Disease Patients Receiving Immunomodulators
Omar Alsaed, Eman Satti, Bassam Muthanna, Safna Veettil, Hadil Ashour, Einas Alkuwari and Samar Al Emadi, Hamad Medical corporation, Doha, Qatar
Background/Purpose: Since the spread of different SARS-CoV2 vaccines over the world, there was an uncertainty of the efficacy and safety of these vaccines in autoimmune…
Abstract Number: 1532 • ACR Convergence 2021
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Rebecca Haberman¹, Ramin Herati¹, David Simon², marie Samanovic¹, Michael Tuen¹, Rebecca Blank³, Sergei Koralov¹, Raja Atreya⁴, Koray Tascilar⁵, Joseph Allen¹, Rochelle Castillo⁶, Amber Cornelius¹, Paula Rackoff³, Gary Solomon⁷, Samrachana Adhikari¹, Natalie Azar⁸, Pamela Rosenthal⁹, Peter Izmirly¹⁰, Jonathan Samuels¹¹, Brian Golden¹², Soumya Reddy⁹, Markus Neurath⁴, Steven B. Abramson¹⁰, Georg Schett¹³, Mark Mulligan¹ and Jose Scher¹⁰, ¹NYU Grossman School of Medicine, New York, NY, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ³New York University, New York, NY, ⁴Deutsches Zentrum fur Immuntherapie, FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone School of Medicine, Hartsdale, NY, ⁸NYU Langone, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹NYU Langone, Rye Brook, NY, ¹²NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY, ¹³Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Patients with immune mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for developing COVID-19. While…
Abstract Number: 1696 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Ongoing Filgotinib RA Long-term Extension Trial of Biologic DMARD Inadequate Responders Initially on Filgotinib or Placebo in a Phase 3 Trial
Maya Buch¹, Tsutomu Takeuchi², Vijay Rajendran³, Jacques-Eric Gottenberg⁴, Alena Pechonkina⁵, YingMeei Tan⁶, Qi Gong⁵, Katrien Van Beneden⁷ and Roberto Caporali⁸, ¹University of Leeds, Leeds, United Kingdom, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Galapagos NV, Mechelen, Belgium, ⁴National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Gilead Sciences, Inc, San Diego, CA, ⁷Galapagos, NV, Mechelen, Belgium, ⁸Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe and Japan. We assessed FIL efficacy and safety in patients…
Abstract Number: 0031 • ACR Convergence 2021
A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
Marion Geoffroy¹, Claire Gozalo², Loic Pauvele², Elise Abboud², Zoubir Djerada³ and Jean hugues Salmon⁴, ¹CHU Reims, France, REIMS, France, ²CHU Reims, Reims, France, ³CHU Riems, Reims, France, ⁴Rheumatology, CHU Maison blanche, Reims, Reims, France
Background/Purpose: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). While therapeutic adherence is essential to the successful management of the patient, an estimated…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0824 • ACR Convergence 2021
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
Peter C Taylor¹, Bruno Fautrel², Yves Piette³, Susana Romero-Yuste⁴, Jasper Broen⁵, Martin Welcker⁶, Elizabeth Holdsworth⁷, Monia Zignani⁸, Katrien Van Beneden⁸, Roberto Caporali⁹ and Rieke Alten¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium, ⁴Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ⁵Maxima Medical Centre, Veldhoven, Netherlands, ⁶MVZ für Rheumatologie, Planegg, Germany, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸Galapagos, NV, Mechelen, Belgium, ⁹Policlinico S. Matteo University, Pavia, Italy, ¹⁰Schlosspark-Klinik University, Berlin, Germany
Background/Purpose: Shared decision making, a cornerstone of rheumatoid arthritis (RA) management1, allows physicians and their patients to make informed decisions about their treatment goals and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].